GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes.
Sign Up to like & getrecommendations! Published in 2024 at "JAMA internal medicine"
DOI: 10.1001/jamainternmed.2024.3806
Abstract: Importance Hyperkalemia is a common complication in people with type 2 diabetes (T2D) that may limit the use of guideline-recommended renin-angiotensin system inhibitors (RASis). Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs) increase urinary… read more here.
Keywords: rates hyperkalemia; use; dpp; glp 1ra ... See more keywords
Pleiotropic effects of GLP-1RAs on peripheral artery disease: Is there any hope?
Sign Up to like & getrecommendations! Published in 2023 at "Diabetes/metabolism research and reviews"
DOI: 10.1002/dmrr.3627
Abstract: NA This article is protected by copyright. All rights reserved. read more here.
Keywords: effects glp; artery disease; peripheral artery; pleiotropic effects ... See more keywords
Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013–2019
Sign Up to like & getrecommendations! Published in 2024 at "Diabetologia"
DOI: 10.1007/s00125-024-06321-2
Abstract: The aim of this study was to investigate racial and ethnic disparities in the use of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor antagonists (GLP-1RAs) among older adults with type 2 diabetes and… read more here.
Keywords: disease; type diabetes; white participants; racial ethnic ... See more keywords
GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2019 at "Endocrine"
DOI: 10.1007/s12020-019-02055-z
Abstract: Some preliminary studies reported a link between GLP-1 receptor agonists (GLP-1RAs) and thyroid/pancreatic neoplasms, while its human relevance remained undetermined. The present meta-analysis was performed to collect information on cancers associated with GLP-1RAs in patients… read more here.
Keywords: risk; glp 1ras; overall cancer; cancer ... See more keywords
The Role of GLP-1RA Medications in Medical Weight Loss and the Positive Impacts on Lipid Management
Sign Up to like & getrecommendations! Published in 2025 at "Current Cardiovascular Risk Reports"
DOI: 10.1007/s12170-025-00761-0
Abstract: Obesity pharmacotherapy is rapidly evolving with the ability of glucagon-like peptide- 1 receptor agonists (GLP-1RAs) to improve atherosclerotic cardiovascular disease (ASCVD) outcomes. This review focuses on how GLP-1RAs impact lipid-related outcomes. Beyond weight reduction, GLP-1RAs… read more here.
Keywords: glp 1ra; 1ra medications; reduction; role glp ... See more keywords
The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy
Sign Up to like & getrecommendations! Published in 2017 at "Advances in Therapy"
DOI: 10.1007/s12325-017-0491-1
Abstract: AbstractThe prevalence and associated clinical burden of type 2 diabetes (T2D) is increasing in the USA and other countries. As a consequence, the role of the pharmacist in managing T2D is expanding, and it is… read more here.
Keywords: glucagon like; glp 1ras; pharmacist managing; type diabetes ... See more keywords
Combining SGLT2is, GLP1-RAs and nsMRAs in Diabetes: A Scoping Review of Current and Future Perspectives
Sign Up to like & getrecommendations! Published in 2025 at "Diabetes Therapy"
DOI: 10.1007/s13300-025-01726-7
Abstract: Combination therapy is a cornerstone of modern type 2 diabetes management, extending beyond traditional goals of glucose, blood pressure, and lipid control to focus on therapies protecting the heart and kidneys. The introduction of sodium-glucose… read more here.
Keywords: combination; type diabetes; sglt2is glp; glp 1ras ... See more keywords
Time to Treatment Intensification with Glucagon-Like Peptide-1 Receptor Agonists Versus Comparators in People with Type 2 Diabetes Treated with Metformin
Sign Up to like & getrecommendations! Published in 2025 at "Diabetes Therapy"
DOI: 10.1007/s13300-025-01751-6
Abstract: Treatment intensification is often required to attain glycemic targets in people living with type 2 diabetes (T2D) but can introduce regimen complexity and increase medication burden. Whether rates of treatment intensification differ by glucose-lowering medication… read more here.
Keywords: treatment; treatment intensification; glucose lowering; time treatment ... See more keywords
Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials.
Sign Up to like & getrecommendations! Published in 2021 at "American heart journal"
DOI: 10.1016/j.ahj.2021.06.001
Abstract: BACKGROUND In international trials, glucagon-like protein-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2Is) were effective in improving cardiovascular (CV) outcomes. METHODS We assessed the effect of GLP-1RAs and SGLT2Is treatment effect on CV endpoints… read more here.
Keywords: glp 1ras; effect; regional variation; variation effects ... See more keywords
Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: a network meta-analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes research and clinical practice"
DOI: 10.1016/j.diabres.2021.108904
Abstract: AIMS To inform clinical practice by comparing and ranking the lowing blood glucose and weight-loss abilities of 8 glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D). METHODS We searched PubMed, EMBASE,… read more here.
Keywords: patients type; glp 1ras; safety; type diabetes ... See more keywords
The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of pharmacology"
DOI: 10.1016/j.ejphar.2020.173823
Abstract: This study was undertaken to assess the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), mainly liraglutide and exenatide, on glycemic control and anthropometric profiles to see if they are effective in treating patients with non-alcoholic… read more here.
Keywords: glucagon like; glp 1ras; effects glucagon; receptor agonists ... See more keywords